sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.